Next Post

Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience

Insud Pharma announced today that it has entered into an agreement with Fresenius Kabi. Under the terms of the agreement Fresenius Kabi will acquire 55% of mAbxience, the global fully-fledged biotech company of the Spanish group. Read More
thehealthco